MedVenture Associates

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

OptiScan Biomedical Corporation, founded in 1994 and located in Hayward, California, specializes in developing bedside blood monitoring systems for critically ill patients in intensive care units (ICUs). The company's flagship product, the OptiScanner 5000, is an automated glucose monitoring platform that utilizes spectroscopy technology to measure plasma glucose levels directly, eliminating the need for calibration. This system enables healthcare providers to rapidly detect changes in glucose levels, thus supporting better management of critically ill patients' health.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

Game Ready is a medical device company specializing in post-surgical orthopedic and sports injury treatment. Its primary product, GameReady, combines active pneumatic compression and adjustable cold therapies to facilitate faster recovery for athletes and patients post-injury or surgery.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.

Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.

Founded in 2004, BeneChill specializes in developing non-invasive cooling technologies aimed at improving patient outcomes following acute ischemic events like cardiac arrest, stroke, and traumatic brain injury. Its flagship product, the RhinoChill System, focuses on reducing patient temperature.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.

Game Ready is a medical device company specializing in post-surgical orthopedic and sports injury treatment. Its primary product, GameReady, combines active pneumatic compression and adjustable cold therapies to facilitate faster recovery for athletes and patients post-injury or surgery.

Founded in 2004, BeneChill specializes in developing non-invasive cooling technologies aimed at improving patient outcomes following acute ischemic events like cardiac arrest, stroke, and traumatic brain injury. Its flagship product, the RhinoChill System, focuses on reducing patient temperature.

Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

EKOS specializes in developing and applying ultrasound technology to treat vascular thrombosis. Its flagship product, the EKOS EkoSonic Endovascular System, enables interventional radiologists, cardiologists, and surgeons worldwide to dissolve blood clots more efficiently and safely.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.

OptiScan Biomedical Corporation, founded in 1994 and located in Hayward, California, specializes in developing bedside blood monitoring systems for critically ill patients in intensive care units (ICUs). The company's flagship product, the OptiScanner 5000, is an automated glucose monitoring platform that utilizes spectroscopy technology to measure plasma glucose levels directly, eliminating the need for calibration. This system enables healthcare providers to rapidly detect changes in glucose levels, thus supporting better management of critically ill patients' health.

eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

EKOS specializes in developing and applying ultrasound technology to treat vascular thrombosis. Its flagship product, the EKOS EkoSonic Endovascular System, enables interventional radiologists, cardiologists, and surgeons worldwide to dissolve blood clots more efficiently and safely.

Aesthera is a California-based company dedicated to advancing high technology aesthetics through its innovative light-based treatment systems. Founded by a team with extensive experience in laser research and development, as well as strong ties to the medical community, Aesthera is known for its pioneering Photopneumatic Therapy (PPx). This groundbreaking therapy offers a range of firsts in the aesthetic treatment field, including painless procedures, no need for pre-treatments, and the ability to treat areas such as legs and backs in under twenty minutes. The company emphasizes safety and efficacy, providing hygienic treatments that are significantly safer and highly effective for both physicians and patients.

Insulet Corporation is a medical device company that develops, manufactures, and markets insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprises a tubeless, disposable insulin pod worn on the body for up to three days and a wireless handheld device that manages dosing, enabling automated, hands-free insulin delivery. The system is sold through independent distributors, pharmacy channels, and direct channels in the United States, Canada, Europe, and the Middle East. Insulet was founded in 2000.

Aesthera is a California-based company dedicated to advancing high technology aesthetics through its innovative light-based treatment systems. Founded by a team with extensive experience in laser research and development, as well as strong ties to the medical community, Aesthera is known for its pioneering Photopneumatic Therapy (PPx). This groundbreaking therapy offers a range of firsts in the aesthetic treatment field, including painless procedures, no need for pre-treatments, and the ability to treat areas such as legs and backs in under twenty minutes. The company emphasizes safety and efficacy, providing hygienic treatments that are significantly safer and highly effective for both physicians and patients.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.

Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.

eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.

Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.

Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.

Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.